Could CAR-T cells tame autoimmune diseases? early trial begins
NCT ID NCT06549296
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a CAR-T cell therapy called RD06-04 in 12 people with active autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves reprogramming a patient's own immune cells to target and destroy faulty B cells. The main goal is to check safety and how the body handles the therapy, with a secondary look at whether it can control disease activity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CAR-T cell therapy (RD06-04) targeting CD19
- What this could lead to
- If successful, this could point toward a new treatment option for people with active autoimmune diseases that are not well-controlled by current therapies.
- What could go wrong
- This is a very early, small trial (12 people) that is currently suspended. It is designed mainly to check safety, so it may not show clear benefit, and CAR-T therapy carries risks like severe immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xuzhou Medical University Affiliated Hospital
Xuzhou, Jiangsu, 221000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.